Richard A. Fair Insider Profile
4 Followers
Richard A. Fair, PRESIDENT AND CEO, Director at Enliven Therapeutics, holds ― shares in Enliven Therapeutics (Ticker: ELVN), holds ― shares in Clovis Oncology (Ticker: CLVSQ), holds 11.81K shares in Bellicum Pharmaceuticals (Ticker: BLCM).
Richard A. Fair's Trading History
| BLCMBellicum Pharmaceuticals | Mar 19, 2020 | ― | Informative Buy | 19.95K | $874.16 | |
| CLVSQClovis Oncology | ― | ― | ― | ― | ||
| ELVNEnliven Therapeutics | ― | PRESIDENT AND CEO, Director | ― | ― |
You May Also Like
Richard A. Fair insider profile FAQ
What is the percentage of profitable transactions made by Richard A. Fair?
The percentage of profitable transactions made by Richard A. Fair is 50%.
What is the average return per transaction made by Richard A. Fair?
The average return per transaction made by Richard A. Fair is -15.40%.
What stocks does Richard A. Fair hold?
Richard A. Fair holds: ELVN, CLVSQ, BLCM stocks.
What was Richard A. Fair's most profitable transaction?
Richard A. Fair’s most profitable transaction was an Informative Buy of BLCM stock on March 19, 2020. The return on the trade was 25.20%.
What is Richard A. Fair's role in Enliven Therapeutics?
Richard A. Fair's role in Enliven Therapeutics is PRESIDENT AND CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
